Phase 2Not yet recruitingAge-related condition

A Study to Evaluate the Effect of Two Fixed-Dose Leucine, Sildenafil and Metformin Combinations on Blood Pressure in Individuals With Hypertension (NS-HTN-01)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Two Fixed-Dose Leucine, Sildenafil and Metformin Combinations (NS-0200) Versus Placebo on Blood Pressure in Individuals With Hypertension

Sponsor
NuSirt Biopharma (Industry)
Enrollment
150 planned
Conditions
Hypertension
Interventions
NS-0200 (low sildenafil); NS-0200 (higher sildenafil); Placebo
Ages
adults, older adults
Registry
NCT07647003

Full record on ClinicalTrials.gov

From the registry

This 12-week, randomized, double-blind, placebo-controlled Phase 2 study will evaluate two fixed-dose oral combinations of L-leucine, sildenafil, and metformin (NS-0200) versus matching placebo in adults 18-75 years with hypertension. Approximately 150 subjects will be screened to randomize \~150 (≈50 per arm) with an expected completer population of \~120. The primary objective is to compare change in mean seated systolic blood pressure from baseline (Day 1) to Week 12 (Day 84) for each NS-0200 dose versus placebo. Secondary outcomes include change in seated diastolic blood pressure and change in body weight. Safety will be monitored through adverse events, labs, vital signs, ECGs, and pregnancy testing.

Primary outcomes

  • Change in systolic blood pressure compared to placebo from baseline to study termination

History

  1. Study completion expected

  2. Primary completion expected

  3. Started

  4. Registered